A proof of concept, single centre, monotherapy, dose-ranging trial to evaluate the efficacy and tolerability of CB0011 at 0,7.5, 15, 30 and 45mg in Obstructive Sleep Apnea.

Trial Profile

A proof of concept, single centre, monotherapy, dose-ranging trial to evaluate the efficacy and tolerability of CB0011 at 0,7.5, 15, 30 and 45mg in Obstructive Sleep Apnea.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs CB 0011 (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Sponsors Cypress Bioscience
  • Most Recent Events

    • 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry Record.
    • 26 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top